Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data contributed by Biodesix and other organizations.

This poster highlights long term patient outcomes from the ctMoniTR Project, a study evaluating the prognostic value of changes in circulating tumor DNA (ctDNA) in patients treated with targeted therapies. The new data release indicates that ctDNA shows promise as an early endpoint to support drug development and regulatory decision-making.

“We are thrilled to partner with our colleagues in industry, academia, government and Friends of Cancer Research in contributing to the new data analysis on ctDNA and outcomes that will be released at the ASCO 2023 Annual Meeting,” said Gary Pestano, Chief Development Officer of Biodesix. “ctDNA continues to show promise, in a range of clinical indications and we are proud to support the efforts to generate evidence on how it can positively impact patient lives.”

The other two abstracts showcase new health economic and outcomes data on the VeriStrat host immune classifier, part of IQLung personalized lung cancer treatment guidance testing. These analyses evaluated healthcare resource utilization (HCRU) and healthcare costs in patients with non-small cell lung cancer (NSCLC) classified by the test. The VeriStrat test is a novel predictive and prognostic blood-based host immune classifier that stratifies immune checkpoint inhibition (ICI) treatment response in patients with advanced NSCLC. Prior studies have shown that patients classified by the test as host immune classifier hot (HIC-Hot), also known as VeriStrat Good, had better outcomes, on average living 2-3 times longer when compared to patients classified as host immune classifier cold (HIC-Cold), also known as VeriStrat Poor.

The first poster, titled “Real-world healthcare resource utilization amongst non-small cell lung cancer (NSCLC) patients tested with a host immune classifier (HIC),” shows that patients with HIC-C classifications have higher HCRU during their lung cancer diagnosis. However, patients with an HIC-H classification had higher HCRU with respect to prescriptions and emergency room visits. The second poster, titled “Real-world healthcare costs amongst non-small cell lung cancer (NSCLC) patients tested with a host immune classifier (HIC),” shows that patients with HIC-C classifications had significantly higher total medical costs through the course of lung cancer diagnosis and treatment than those with an HIC-H classification.